Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic GVHD is the most common late complication following allogeneic stem cell transplantation. It has features resembling autoimmune disorders such as scleroderma, primary biliary cirrhosis, bronchiolitis obliterans, chronic immunodeficiency etc. Thus, chronic GVHD can lead to debilitating complications such as joint contractures, blindness, end-stage lung disease, etc so that chronic GVHD has a major impact both on survival as well as quality of life. Although its pathogenesis is still poorly unclear, it has been reported since 2000 that B cell-mediated immunity may also contribute to development of chronic GVHD other than T cells. Thus, targeting against B cell may be a useful treatment strategy in the treatment of chronic GVHD.

The purpose of this study is to determine whether rituximab, an anti-CD20 monoclonal kimeric antibody is effective in the treatment of chronic graft-versus-host disease (chronic GVHD) refractory to steroid.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628

Leukemia, Mast-Cell Mantle-cell Lymphoma

COMPLETED PHASE2

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232

Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia +5 more

TERMINATED PHASE2

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

NCT07012304

Chronic Graft Versus Host Disease

RECRUITING PHASE1/PHASE2

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

NCT01044745

Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission +108 more

TERMINATED PHASE2

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

NCT02145403

Hematologic Malignancies Relapse Graft-Versus-Host Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. STUDY OBJECTIVES

* Primary Endpoints: To assess the response rate
* Secondary End points

* To evaluate the discontinuation of corticosteroid
* To assess the quality of life
2. Treatment schedule

* The BSA on the date of every treatment cycle may be used as the same value of baseline BSA, if change of body weight is within 10% of baseline body weight.
* Treatment schedule consists of induction and maintenance therapy as follows

* Induction - Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks
* Maintenance - Rituximab 375 mg/m2 monthly IV for 4 consecutive months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Steroid-Refractory Chronic GVHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Rituximab treatment arm

Group Type EXPERIMENTAL

Rituximab

Intervention Type DRUG

Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks

Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks

Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mabthera

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All recipients underwent allogeneic stem cell transplantation for haematologic disorders
* All recipients diagnosed as chronic GVHD according to diagnostic criteria proposed by National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD

* The presence of one diagnostic sign Or
* The presence of one distinctive sign (Appendix 1B) with laboratory or histopathologic confirmation in the same or other organ if diagnostic feature is not present
* All patients with chronic GVHD have at least moderate score based on the global scoring system of chronic GVHD
* Recipients refractory or resistant to therapy with corticosteroid

* Patients had chronic GVHD with the same severity during the last one month while they had received the equivalent of prednisone ≥0.5mg/kg per day or 1mg/kg every other day at least for 30 days or longer
* Informed consent
* Other concomitant medication

* Patients treated with other immunosuppressive agents (cyclosporine, thalidomide etc) as a combination therapy with corticosteroid must be receiving a dosage that has been stable for at least 1 month prior to screening.

Exclusion Criteria

* Recipients received donor lymphocyte infusions in the preceding 100 days
* Serious comorbid diseases
* Life expectancy of less than 1 month
* Age \< 2 years and \> 75 years
* Pregnant or intended to become pregnant
* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy

Minimum Eligible Age

3 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No